Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

Next Previous
Search
Trial Profile

A Phase 1b/2a Dose-escalation and Safety/Efficacy Evaluation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With Cemiplimab (REGN2810; Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; Pexastimogene devacirepvec (Primary) ; Pexastimogene devacirepvec (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REN026
  • Sponsors SillaJen Biotherapeutics

    • Most Recent Events

    • 25 Oct 2024 Results assessing the AI-powered Lunit SCOPE IO spatial analyzer to assess TILs in metastatic renal cell carcinoma (mRCC) patients undergoing combination therapy with Pexa-vec and cemiplimab presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
    • 04 Jun 2024 Results assessing the correlation between plasma cytokine/chemokine levels and the efficacy of Pexa-Vec and cemiplimab, proposing that these biomarkers could predict treatment outcomes and contribute to more personalized cancer treatment protocols, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 27 Mar 2024 Status changed from active, no longer recruiting to completed, according to a SillaJen Biotherapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top